Health & Wellbeing

Viclink leads Wellington biotech in Philadelphia

health-biotech

Published Jun 5, 2019

A team of Viclinkers are in Philadelphia for the Bio International Convention, one of the world’s largest biotech and pharmaceutical conventions. BIO2019 is an un-paralleled partnering, education and networking opportunity and more than 16,000 attendees from 67 countries are expected. 

There will be more than just a few Kiwis attending, with Viclink forming part of the New Zealand Pavilion at the Convention (pictured above). Led by the Ministry of Business, Innovation and Employment (MBIE), the New Zealand Pavilion will showcase biotech pioneers from across Aotearoa, including Honeylab, Kode Biotech, plus Viclink spin-outs, AuramerBio and Avalia Immunotherapies. 

Viclink will be proudly representing a number of Wellington connections, including GlycoSyn, Malaghan Institute of Medical Research and the New Zealand Health Innovation Hub, sharing the message that Wellington is genuinely a gateway to world-leading biotech. 

The exposure to a number of industry thought leaders, and ability to meet directly with potential pharmaceutical partners is what makes BIO so valuable. The Viclink team, including Anne Barnett, CEO and Senior Commercialisation Managers Janice Cheng, Jeremy Jones and Matthew Nicholson, will be working hard meeting with global biotech and pharma organisations, seeking feedback on a number of Victoria University of Wellington technologies that are currently in early-stage development. 

Technology ranging from anti-cancer therapeutics to bone regeneration drugs, animal health technology to medical devices will be presented by the Viclink team. The aim is to get quality feedback that can lead into further development of the technology and potential future partnerships.